دورية أكاديمية
Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
| العنوان: | Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer. |
|---|---|
| المؤلفون: | Martinez-Mugica Barbosa C; Cristina Martinez-Mugica Barbosa, Pharmacy Department, Cabueñes Hospital, Los Prados, Gijon, Spain. cmartinezmugica@gmail.com., Cercós Lletí AC, Pampín Sánchez R, Durán Román C, Terroba Alonso P, Fernández González B |
| المصدر: | Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2022 Dec; Vol. 35 (6), pp. 551-558. |
| نوع المنشور: | Observational Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sociedad Española de Quimioterapia Country of Publication: Spain NLM ID: 9108821 Publication Model: Print Cited Medium: Internet ISSN: 1988-9518 (Electronic) Linking ISSN: 02143429 NLM ISO Abbreviation: Rev Esp Quimioter Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: [Barcelona] : Sociedad Española de Quimioterapia Original Publication: Barcelona : J.R. Prous, S.A., [1988- |
| مواضيع طبية MeSH: | Anti-Bacterial Agents*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Immune Checkpoint Inhibitors*/therapeutic use , Lung Neoplasms*/drug therapy, Female ; Humans ; Male ; Nivolumab/therapeutic use ; Retrospective Studies ; Immunotherapy ; Fluoroquinolones ; beta-Lactams |
| مستخلص: | Objective: Recent research suggests that the use of antibiotics could reduce the efficacy of checkpoint inhibitors, in addition to other well-known factors. It could be due to gut microbiota modification, which impact over the immune system response. However, the information available so far is contradictory. The objective of this research was to clarify whether antibiotic use influences efficacy of checkpoint inhibitors treatments in non-small cell lung cancer patients in clinical practice. Methods: Therefore, a retrospective observational study was designed. Use of antibiotics among patients treated with atezolizumab, pembrolizumab or nivolumab was assessed within 2 months of checkpoint inhibitors treatments initiation. Results: A total of 140 patients were included, mostly men, with good performance status (ECOG 0-1), all of them previously treated with chemotherapy. An antibiotic prescription was identified in 31% of these patients, mainly fluoroquinolones or beta-lactams. The most frequent indication was respiratory infection. Both progression-free survival and overall survival were lower for patients treated with anti-infective drugs, although this difference was not statistically significant. Conclusions: More studies are needed to draw conclusions about the impact of antibiotics on the efficacy of immunotherapy. (©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).) |
| References: | Clin Transl Oncol. 2019 Jan;21(1):3-17. (PMID: 30446985) Lancet. 2017 May 13;389(10082):1931-1940. (PMID: 28513453) J Immunother Cancer. 2019 Jul 10;7(1):176. (PMID: 31292005) J Clin Med. 2019 Jul 10;8(7):. (PMID: 31295966) Ann Oncol. 2016 Sep;27(suppl 5):v1-v27. (PMID: 27664245) Trends Immunol. 2012 Sep;33(9):459-66. (PMID: 22677185) Exp Hematol Oncol. 2019 Aug 22;8:19. (PMID: 31463163) Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869) JAMA Oncol. 2019 Dec 1;5(12):1774-1778. (PMID: 31513236) Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. (PMID: 31745593) Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494) Anticancer Res. 2017 Jun;37(6):3195-3200. (PMID: 28551664) Oncologist. 2020 Jan;25(1):55-63. (PMID: 31292268) Oncol Lett. 2019 Mar;17(3):2946-2952. (PMID: 30854072) Ann Oncol. 2018 Jun 1;29(6):1437-1444. (PMID: 29617710) J Thorac Oncol. 2020 Jul;15(7):1147-1159. (PMID: 32173463) Oncogene. 2012 Nov 15;31(46):4811-4. (PMID: 22266863) N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635) Lung Cancer. 2019 Apr;130:10-17. (PMID: 30885328) Nat Med. 2018 Dec;24(12):1804-1808. (PMID: 30420754) Lung Cancer. 2019 Jun;132:72-78. (PMID: 31097097) J Thorac Oncol. 2016 Sep;11(9):1411-22. (PMID: 27296106) |
| فهرسة مساهمة: | Keywords: antibiotics; antineoplastic agents; efficacy; immunotherapy |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Immune Checkpoint Inhibitors) 31YO63LBSN (Nivolumab) 52CMI0WC3Y (atezolizumab) DPT0O3T46P (pembrolizumab) 0 (Fluoroquinolones) 0 (beta-Lactams) |
| تواريخ الأحداث: | Date Created: 20220927 Date Completed: 20221201 Latest Revision: 20221223 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9728602 |
| DOI: | 10.37201/req/040.2022 |
| PMID: | 36164854 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1988-9518 |
|---|---|
| DOI: | 10.37201/req/040.2022 |